Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Kaspersky schreef op 28 maart 2020 23:04 :
[...]
Technisch -> naar beneden maandag op $70,00 - $71,00.
Dinsdag wordt mogelijk $74,00 weer getest.
Gilead blijft bij mij long in de portefeuille staan.
Dit verwacht ik ook. Ben benieuwd naar 3 April. Wat verwacht jij, zal de koers enorm omhoog gaan?
Imjustabeginner schreef op 28 maart 2020 23:07 :
[...]
Dit verwacht ik ook. Ben benieuwd naar 3 April. Wat verwacht jij, zal de koers enorm omhoog gaan?
Technisch bepaald niet exact wat er gaat gebeuren; het lijkt erop dat we volgende week of de week daarop ook de $78,00 gaan testen. En dat zou best 3 april 2020 kunnen zijn: technisch is geen exacte voorspelling. Ik voorzie bijvoorbeeld een explosieve stijging maar wel binnen een periode van 2 jaar (vrij ruim). De 78,00 dollar lijkt binnenkort weer in beeld te komen. De algoritmen kunnen de koers nog 2 jaar zijwaarts laten gaan (als je dividend meerekent is het nog steeds een stijging); om daarna als iedereen eruit is geschud met grotere percentages te gaan stijgen.
Gilead CEO: We're on track to have initial data in the coming weeks Mar. 28, 2020 6:19 PM ET|About: Gilead Sciences, Inc. (GILD)|By: SA Eli Hoffmann, SA News Editor In an open letter, Gilead (NASDAQ:GILD) CEO Daniel O'Day says he expects to have initial data about the potential of remdesivir to combat coronavirus "in the coming weeks." "When the news of the coronavirus first emerged, Gilead immediately began to investigate the potential of remdesivir, a medicine we had been studying for many years as part of our extensive research in antivirals. Remdesivir had never been approved for use but based on what we had learned to date, we knew it might have potential with the novel coronavirus. Since then, we have been working with the greatest sense of urgency and responsibility to determine whether remdesivir does indeed work against COVID-19," he writes. "Multiple studies are ongoing, and we are on track to have initial data in the coming weeks. If it is approved, we will work to ensure affordability and access so that remdesivir is available to patients with the greatest need. "In the meantime, we have made the investigational medicine available for severely ill patients who cannot enroll in a trial. This 'compassionate use' program is typically reserved for a small number of individual cases but there is nothing typical about this crisis and to date we have provided remdesivir to more than 1,000 patients. "With expanded access, hospitals or physicians can apply for emergency use of remdesivir for multiple severely ill patients at a time. While it will take some time to build a network of active sites, this approach will ultimately accelerate emergency access for more people." Als gilead slechte resultaten terug zou hebben gekregen op de meer dan 1000 patienten aan wie al remdesivir al is verstrekt zouden ze dit persbericht waarschijnlijk niet zo proactief naar buiten hebben gebracht.
seekingalpha.com/article/4334581-gile... Ook goed om de kritische signalen tot je te nemen dat trials vaak tegenvallen.
Steking alpha Gilead CEO: We're on track to have initial data in the coming weeks Mar. 28, 2020 6:19 PM ET|About: Gilead Sciences, Inc. (GILD)|By: SA Eli Hoffmann, SA News Editor In an open letter, Gilead (NASDAQ:GILD) CEO Daniel O'Day says he expects to have initial data about the potential of remdesivir to combat coronavirus "in the coming weeks." "When the news of the coronavirus first emerged, Gilead immediately began to investigate the potential of remdesivir, a medicine we had been studying for many years as part of our extensive research in antivirals. Remdesivir had never been approved for use but based on what we had learned to date, we knew it might have potential with the novel coronavirus. Since then, we have been working with the greatest sense of urgency and responsibility to determine whether remdesivir does indeed work against COVID-19," he writes. "Multiple studies are ongoing, and we are on track to have initial data in the coming weeks. If it is approved, we will work to ensure affordability and access so that remdesivir is available to patients with the greatest need. "In the meantime, we have made the investigational medicine available for severely ill patients who cannot enroll in a trial. This 'compassionate use' program is typically reserved for a small number of individual cases but there is nothing typical about this crisis and to date we have provided remdesivir to more than 1,000 patients. "With expanded access, hospitals or physicians can apply for emergency use of remdesivir for multiple severely ill patients at a time. While it will take some time to build a network of active sites, this approach will ultimately accelerate emergency access for more people." Last week, Gilead dropped its orphan drug designation for remdesivir, a status granted by the FDA that would have extended monopoly rights for the drug if it came on the market.
Er zijn meerdere biotech die mogelijk een medicijn hebben voor Covid 19. Het zou leuk zijn als Gilead het heeft en de productie flink kan opschalen, maar persoonlijk zou ik het niet erg vinden als andere biotechbedrijven deze prijs binnenslepen. Gilead heeft ook goede diversificatie; een medicijn voor Covid 19 zou bij succes wel de oorzaak kunnen zijn voor de explosieve stijgingen. Tussen nu en 2022 verwacht ik explosieve stijgingen -> opvallend zijn de extra bewegingen van de afgelopen tijd. Mogelijk om wat aandelen los te krijgen.
Jansens is ook in snelvaart voor vaxin. Zijn nu uit selectie van 10 naar 1 aan het afronden
amp.usatoday.com/amp/2934583001?__twi... To expedite access, the company announced Saturday it had begun transitioning to a system using an "expanded access" program. This allows hospitals or physicians to apply for emergency use of remdesivir for multiple severely ill patients at a time. We are doing this before knowing whether the drug is safe and effective to treat COVID-19 because of the urgency of the situation,” a company spokeswoman said via email.
Voor de derde keer in korte tijd zit GLD met koers rond $79/80,- In de boekjes vroeger grote kans op doorbraak. Pat op zich ook wel bij het nieuws wat er speelt, maar dat acht ik bij de tweede bounce ook al. Wat verwachten jullie?
Gilead nearing finish line on Forty Seven buy Mar. 30, 2020 8:40 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W. House, SA News Editor Gilead Sciences (NASDAQ:GILD) announces the expiration of the HSR waiting period regarding its previously announced acquisition of Forty Seven (NASDAQ:FTSV) for ~$4.9B. The transaction should close in early April. GILD is up 3% premarket on the advancement of remdesivir for the treatment of COVID-19.
Bakkiekoffie schreef op 30 maart 2020 16:13 :
Voor de derde keer in korte tijd zit GLD met koers rond $79/80,-
In de boekjes vroeger grote kans op doorbraak.
Pat op zich ook wel bij het nieuws wat er speelt, maar dat acht ik bij de tweede bounce ook al. Wat verwachten jullie?
Sorry, ik zag verkeerde koers. (Teveel positief zonlicht). We zitten in de € 76,- Dus vraag is nog niet opportuun
Kasperky , Apache corp. wat denkt u daarvan? ( vind heel weinig informatie )
Good Reason To Be Hopeful For Gilead's Remdesivir Mar. 31, 2020 2:33 PM ET|12 comments | About: Gilead Sciences, Inc. (GILD) Richelle Cutler-Strom Richelle Cutler-Strom Long/short equity, Growth, growth at reasonable price, short-term horizon (221 followers) Summary Gilead is testing efficacy of remdesivir against the novel coronavirus (COVID-19) in multiple international trials. Remdesivir prevented severe lung damage from MERS coronovirus infection in a mouse and monkey model. Preclinical data and an explanation for the Ebola trial failure indicate that remdesivir will be a successful treatment for COVID-19. Inevitable remdesivir licensing deals, with exclusivity until 2034, and its forthcoming marketing of a blockbuster arthritis drug, filgotinib, will increase Gilead's revenue significantly. Gilead Sciences Inc. (NASDAQ:GILD) is currently testing remdesivir in multiple human trials for efficacy against the novel coronavirus (COVID-19). Remdesivir is an adenosine nucleotide prodrug that inhibits replication in a broad range of viruses (Arenaviridae, Coronaviridae, Filoviridae, Flaviviridae, and Paramyxovirida) in vitro. Remdesivir reduced lung damage inflicted from the MERS coronavirus in mice and monkeys. The animal studies showed that optimal therapeutic efficacy requires early dosing. However, MERS patients were found to have prolonged viral replication, so remdesivir may still benefit the most severe coronavirus cases. Remdesivir failed in Ebola virus trials even though remdesivir inhibited Ebola virus replication in vitro and in a monkey study. These preclinical studies indicated that remdesivir would be effective against the Ebola virus in humans. So, what went wrong? Could disappointment be around the corner for remdesivir in the COVID-19 trials? The Ebola monkey study showed that a high remdesivir concentration (10 mg/kg) was critical for maximum suppression. The trial also indicated that too high a concentration, over consecutive days, could cause liver injury. Gilead played it safe by using a low dosage in the Ebola trial (~3 mg/kg loading dose, 1.5 mg/kg maintenance dose, assuming a 66 kg patient). Thus, the dosage may not have reached an effective concentration in all cell types. Furthermore, Ebola causes systemic intravascular coagulation, which could have restricted remdesivir circulation through organs. The stronger efficacy of the Ebola targeting antibodies could be attributed to their ability to enter the lymphatic system, circumventing the coagulated capillaries - the antibodies could reach infected cells, whereas remdesivir could not. Gilead is using the same remdesivir dosage in the COVID-19 trials as used in the Ebola trial. Fortunately, COVID-19 infected patients do not have circulatory problems. Also, COVID-19 targets the lungs, and remdesivir robustly inhibits COVID-19 replication in human airway epithelial cells in vitro. The selected trial dosage is based on the effective in vitro inhibitory concentration along with in vivo pharmacokinetics and toxicity data. Accordingly, lung epithelial cells of COVID-19 infected patients receive an effective concentration of remdesivir. Remdesivir may also be more readily incorporated into coronavirus RNA than Ebola RNA since remdesivir appears to have a higher affinity for the coronavirus polymerase than the Ebola polymerase. A blogger recently opined remdesivir's unpredictable success based on the poor performance of a similar type of drug, favipiravir. However, favipiravir has never been reported to inhibit coronavirus replication (figure 2). Moreover, many nucleoside analogues fail to inhibit virus replication because the virus’s proofreading nuclease detects and removes them. Remdesivir mostly evades proofreading by the coronavirus exoribonuclease, thus allowing incorporation and viral inhibition. Nucleoside and nucleotide analogues are tried and true antiviral drugs, making up almost half of all antivirals. Chloroquine is another antiviral that has shown promise in treating COVID-19. Unfortunately, chloroquine can have serious side effects such as vomiting, diarrhea, nausea, and headache. These side effects may be particularly hazardous in ill COVID-19 patients and is out of the question for intubated patients. RNA viruses have high mutation rates and mutations in COVID-19 surface glycoproteins could eventually make the current vaccines under development less effective. An annual vaccine version, like the flu vaccine, may be necessary. Moreover, vaccines produce less protection in the elderly. Thus, a vaccine will not make remdesivir obsolete. Remdesivir's efficacy relies on polymerase nucleotides conserved across diverse coronavirus strains. This indicates that remdesivir will be front-line therapy for today's COVID-19 and tomorrow's new coronavirus strain. Gilead's first remdesivir patent filing was in 2014, which gives Gilead exclusivity rights until 2034. The first remdesivir trial result from China has an estimated primary completion date of April 3rd. With a life-saving treatment in high demand, the analysis could be expedited. Good news could be just around the corner. Financials Gilead's revenue growth has been low, with the 12 months trailing growth at a paltry 1.2%. However, Gilead still has a reasonable P/E of 17.3 and earnings will grow markedly if Gilead receives licensing revenue from remdesivir. In addition, Gilead and Galapagos (NASDAQ:GLPG) will soon bring Filgotinib to market for treating rheumatoid arthritis. Filgotinib will compete with AbbVie's (NYSE:ABBV) Rinvoq, but Gilead is hoping its strong safety record prevents a black box warning, making filgotinib the preferred treatment. Filgotinib's approval for treating other inflammatory diseases, such as Ulcerative colitis, Crohn's disease, Psoriatic arthritis, and Ankylosing spondylitis, will soon follow. The potential worldwide sales of these indications are in the billions.
www.timesofisrael.com/israeli-doctor-... In Padua, the autoimmune medicine Tocilizumab has proven effective, but can only be used once it is established that no other viruses or bacteria are present in the patients’ bodies, he said. The hospital where he works has also seen positive results from the antiviral drug Remdesivir, he added. Een ervaring van een arts in italie.
Gilead Sciences launches two remdesivir studies in UK Apr. 1, 2020 7:57 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W. House, SA News Editor Gilead Sciences (NASDAQ:GILD) has initiated two Phase 3 clinical trials in the UK evaluating remdesivir in moderately-to-severely ill COVID-19 patients. 15 sites will be initially involved.
Endless schreef op 1 april 2020 14:20 :
Gilead Sciences launches two remdesivir studies in UK
Apr. 1, 2020 7:57 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W. House, SA News Editor
Gilead Sciences (NASDAQ:GILD) has initiated two Phase 3 clinical trials in the UK evaluating remdesivir in moderately-to-severely ill COVID-19 patients. 15 sites will be initially involved.
Gelukkig zijn er genoeg proefpersonen........
Esco schreef op 29 maart 2020 07:17 :
Jansens is ook in snelvaart voor vaxin. Zijn nu uit selectie van 10 naar 1 aan het afronden
Janssen gaat hun vaccin voor de kostprijs verkopen.
DeZwarteRidder schreef op 1 april 2020 14:32 :
[...]
Gelukkig zijn er genoeg proefpersonen........
Je bedoelt...helaas, zijn er genoeg proefpersonen..
nypost.com/2020/03/20/coronavirus-in-... Meer positieve gevallen. Hopelijk duurt het niet lang meer voor de uitkomsten van de trials bekend worden, eerste in china liep af op 3 april.
www.acsh.org/news/2020/03/31/will-rem... Werking remdesivir als middel tegen mers (ander coronavirus) bij apen,
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)